Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/9949
Type: Journal article
Title: Considerations for the safe prescribing and use of COX-2-specific inhibitors
Author: Barraclough, D.
Bertouch, J.
Brooks, P.
Brown, M.
Cleland, L.
Clemens, L.
Crowley, S.
Day, R.
DeJager, J.
Edmonds, J.
Fletcher, P.
Franks, G.
Harris, D.
Horowitz, J.
Johnston, M.
Kerr, S.
Littlejohn, G.
MacDonald, G.
McColl, G.
Sambrook, P.
et al.
Citation: Medical Journal of Australia, 2002; 176(7):328-331
Publisher: Australasian Med Publ Co Ltd
Issue Date: 2002
ISSN: 0025-729X
1326-5377
Organisation: The Australian CSI Working Group
Statement of
Responsibility: 
David R Barraclough, James V Bertouch, Peter Brooks, Mark A Brown, Leslie G Cleland, Laurie E Clemens, Steven J Crowley, Richard O Day, Julien P DeJager, John P Edmonds, Peter J Fletcher, Gary R Franks, David C Harris, John D Horowitz, Michael D Johnston, Stephen J Kerr, Geoff O Littlejohn, Graham J MacDonald, Geoff J McColl, Phillip N Sambrook, Sepehr Shakib, Murray W Verso and Neville D Yeomans
Abstract: The majority of the "Australian COX-2-Specific Inhibitor (CSI) Prescribing Group" endorse the following points: CSIs are equivalent to non-steroidal anti-inflammatory drugs (NSAIDs) as anti-inflammatory agents. CSIs and NSAIDs modify symptoms but do not alter the course of musculoskeletal disease. CSIs do not eliminate the occurrence of ulcers or their serious complications, but are associated with considerably fewer peptic ulcers, slightly fewer upper GI symptoms and, according to published reports, fewer serious upper GI complications, notably bleeding, than CSIs and NSAIDs have similar effects on renal function and blood pressure. Whether any CSI poses a risk to cardiovascular safety remains subject to debate. Comorbidities and coprescribed drugs must be considered before initiating CSI (or NSAID) therapy. Patients prescribed CSIs (or NSAIDs) should be reviewed within the first few weeks of therapy to assess effectiveness, identify adverse effects and determine the need for ongoing therapy.
Keywords: Humans; Gastrointestinal Diseases; Kidney Diseases; Cardiovascular Diseases; Sulfonamides; Lactones; Sulfones; Pyrazoles; Isoenzymes; Membrane Proteins; Cyclooxygenase Inhibitors; Physician's Practice Patterns; Prostaglandin-Endoperoxide Synthases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors
Description: © 2002 The Medical Journal of Australia
RMID: 0020020215
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.